Commvault Systems Inc vs Zoetis Inc — how do they compare? Commvault Systems Inc trades at $141.56 (market cap $5.78B), while Zoetis Inc trades at $73.62 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 5.4× Commvault Systems Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Commvault Systems Inc pays none. Which is the better fit depends on your goals.
| CVLT | ZTS | |
|---|---|---|
Market Cap | $5.78B | $31.14B |
Sector | Technology | Health |
52-Week High | $195.41 | $156.76 |
52-Week Low | $75.18 | $71.91 |
Enterprise Value | $5.76B | $38.70B |
Dividend Yield | — | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $140.52, up 0.78% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, 81% gross margins, and 32.77% ROE, though valuation metrics appear elevated with P/E at 89.35. Recent news highlights positive developments including Threat Scan integration with Google and strong Q1 2027 results with 16% subscription revenue growth.
CVLT presents growth potential with 22% ARR growth and analyst consensus target of $172.40 (23% upside), but faces risks from fiduciary investigations and high valuation multiples. The stock's technical strength and fundamental execution support bullish sentiment, though investors should monitor the ongoing legal scrutiny and margin compression from 7.64% to 5.61% net margin projection.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Trailing returns across standard periods
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →